Dynamix Pharmaceuticals Completes a $10M Series A Financing
Signs a Collaboration Deal with Teva Pharmaceutical Industries
Advertisement
Dynamix Pharmaceuticals announced that they have closed a $10 million financing round. The financing was led by Batsheva Elran, Founder and Managing Partner of Opal Ventures, as a Medica3 fund investment with Teva Pharmaceutical Industries Ltd.
Dynamix Pharmaceuticals, founded by Dr. Oren M. Becker, who serves as its President and CEO, also announced that it has signed a collaboration and licensing agreement with Teva Pharmaceutical Industries Ltd. for the discovery and development of up to two of Dynamix drug candidates.
Under the terms of the agreement, Dynamix will be eligible to earn milestones based on the achievement of certain discovery, development, regulatory and commercial milestones. Dynamix will also receive tiered royalties on sales by Teva of the collaboration-developed product sales.